Metastatic Colorectal Carcinoma, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
Conditions
Brief summary
This phase I trial is to find out the best dose, possible benefits, and/or side effects of riluzole and how well it works in combination with standard of care mFOLFOX6 and bevacizumab in treating patients with colorectal cancer that has spread to other places in the body (metastatic). Riluzole is a well-tolerated oral medication that has demonstrated it may make chemotherapy work better. Chemotherapy drugs, such as oxaliplatin, leucovorin calcium and fluorouracil, work in different ways to stop the growth of \[cancer/tumor\] cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is an antibody that targets the blood vessel by blocking the activity of a protein called vascular endothelial growth factor alpha (VEGF-A). It helps to make the mFOLFOX6 more effective. Giving riluzole, mFOLFOX6, and bevacizumab may kill more tumor cells compared to mFOLFOX6 and bevacizumab alone in treating patients with colorectal cancer.
Detailed description
PRIMARY OBJECTIVE: I. Characterize the safety and toxicity of riluzole in combination with modified (m) leucovorin calcium, fluorouracil, and oxaliplatin (FOLFOX) 6/bevacizumab and determine the recommended phase II dose (RP2D) of riluzole in combination with mFOLFOX6/bevacizumab in patients with metastatic colorectal cancer. SECONDARY OBJECTIVE: I. Determine the pharmacokinetics of riluzole in patients with metastatic CRC. EXPLORATORY OBJECTIVES: I. Assess the efficacy of the combination treatment. II. Determine the effect of riluzole in downstream GRM3 signaling by immunofluorescent staining of phosphorylated (p)AKT and pCREB in pre- and post-treatment tumor tissues. III. Assess FCGRT/FcRn expression, bevacizumab pharmacokinetics, inflammatory cytokines, and cachexia associated factors as early biomarkers for resistance to therapy. IV. Assess cytotoxic T cells in peripheral blood to evaluate the immunomodulatory effect of this therapy. OUTLINE: This is a dose-escalation study of riluzole. Patients receive riluzole orally (PO) twice daily (BID) on days 1-14. Patients also receive oxaliplatin via intravenous piggyback (IVPB) over 2 hours, leucovorin calcium IVPB over 2 hours, and bevacizumab IVPB over 30 minutes on day 1 and fluorouracil via intravenous (IV) push over 5 minutes and then IV continuously over 46 hours on days 1-2. Treatment repeats every 2 weeks for up to 8 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 30 days.
Interventions
BIOLOGICALBevacizumab
Given IVPB
DRUGFluorouracil
Given IV
DRUGLeucovorin Calcium
Given IVPB
DRUGOxaliplatin
Given IVPB
DRUGRiluzole
Given PO
Sponsors
Ning Jin
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with metastatic colorectal cancer, who are appropriate candidates to receive mFOLFOX6/bevacizumab. Patients who progressed on FOLFOX-based regimen are allowed * Willingness to undergo both pre-treatment and post-treatment tumor tissue biopsies (pre-treatment tumor tissue will be sent to pathology lab to confirm metastatic colorectal cancer as the standard of care) * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Age \>= 18 years * Absolute neutrophil count \>= (ANC) 1,500/ul * Platelets \>= 100,000/ul * Hemoglobin \>= 9 g/dl * Serum total bilirubin \< 1.5 x ULN * Serum albumin \>= 2.5 g/dl * If no liver involvement, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 1.5 x ULN. If liver involvement, AST and ALT =\< 3.0 x ULN * Ability to understand and the willingness to sign a written informed consent document * A male subject of fathering potential must use an adequate method of contraception to avoid conception throughout the study (and for up to 12 weeks after the last dose of study drug) to minimize the risk of pregnancy. If the partner is pregnant or breastfeeding, the subject must use a condom * Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the last dose of study drug to minimize the risk of pregnancy. WOCBP must have a negative serum or urine pregnancy test within 72 hours before the start of the investigational product
Exclusion criteria
* Patients who are receiving any other investigational agents * Patients with history of hepatitis B or C * Patients with severe renal impairment (CrCl \< 30 mL/min) * Prior full field radiotherapy \< 4 weeks or limited field radiotherapy \< 2 weeks prior to first study drug administration. Patients with central nervous system (CNS) metastases may participate in this trial provided they are clinically stable. Patients who are \< 1 month from radiation therapy must not be included * Patients with existing grade 2 peripheral neuropathy * Patients with a history of thrombotic or embolic events within the last six months such as a cerebrovascular accident (including transient ischemic attacks), pulmonary embolism or deep vein thrombosis * Cardiac conditions as follows: * Active coronary artery disease, unstable or newly diagnosed angina or myocardial infarction less than 6 months prior to first study drug administration * Class III-IV New York Heart Association (NYHA) congestive heart failure * Uncontrolled hypertension (Systolic blood pressure \[BP\] \> 150 mmHg and diastolic BP \> 90 mmHg for 24 hours) despite optimal medical management * Corrected QT (QTc) (Friderica) prolongation \> 480 msec * Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, cardiac arrhythmia, active bleeding diatheses, and psychiatric illness/social situations that would limit compliance with study requirements * Major surgical procedure or significant traumatic injury less than 3 weeks or those who receive minor surgical procedures within 1 week from first dose of study drug administration * Known inability to swallow capsules * Inability to comply with study and/or follow-up procedures * Pregnant women are excluded from this study. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose limiting toxicities (DLTs) | Up to 4 weeks (2 cycles of treatment) (1 cycle = 14 days) | Will be defined by treatment related grade \>= 4 adverse events or \>= grade 3 alanine aminotransferase or aspartate aminotransferase elevation during the DLT period using the Common Terminology Criteria for Adverse Events version 5.0. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic (PK) profile of riluzole (Cmax) | Day 1 on cycle 1 (each cycle is 14 days) | K data analysis will utilize a nonlinear mixed effects approach whereby PK parameter estimates will be generated from the data, and 'dose day' will be evaluated as a covariate on clearance and volume of distribution. The PK parameters including Cmax. Peak Plasma Concentration (Cmax) |
| Pharmacokinetic (PK) profile of riluzole (AUC) | Day 1 on cycle 1 (each cycle is 14 days) | PK data analysis will utilize a nonlinear mixed effects approach whereby PK parameter estimates will be generated from the data, and 'dose day' will be evaluated as a covariate on clearance and volume of distribution. The PK parameters including AUC. Area under the plasma concentration versus time curve (AUC) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change in bevacizumab clearance (Cmax) | Day 1 of cycle 1, 3, 5, 7 (each cycle is 14 days) | Peak Plasma Concentration (Cmax) |
| Change in bevacizumab clearance (AUC) | Day 1 of cycle 1, 3, 5, 7 (each cycle is 14 days) | Area under the plasma concentration versus time curve (AUC) |
| interleukin 6 | Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days) | Cytokines |
| leukemia inhibitory factor | Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days) | Cytokines |
| Necrosis factor alpha | Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days) | Cytokines |
| Interferon gamma | Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days) | Cytokines |
| Objective response rate (complete response + partial response) | Up to 112 days | Will be estimated along with exact 95% confidence interval. |
| ferritin | Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days) | Cytokines |
| metalloproteinases 1 | Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days) | Cytokines |
| body weight | Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days) | Will include body weight and summarized using mean +/- standard error of mean, range, and median at each time point. Graphical analyses will be largely used to assess potential patterns and relationships. |
| skeletal muscle index | Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days) | Will include skeletal muscle index and summarized using mean +/- standard error of mean, range, and median at each time point. Graphical analyses will be largely used to assess potential patterns and relationships. |
| body serum albumin | Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days) | Will include body serum albumin and summarized using mean +/- standard error of mean, range, and median at each time point. Graphical analyses will be largely used to assess potential patterns and relationships. |
| Change in levels of circulating cytotoxic T cells | Day 1 of Cycle 1,3,5,7 (each cycle is 14 days) | Will be assessed using peripheral blood mononuclear cells and summarized using mean +/- standard error of mean, range, and median at each time point. Graphical analyses will be largely used to assess potential patterns and relationships. |
| C-reactive protein | Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days) | Cytokines |
| Change in phosphorylated (p)AKT and pCREB levels | Up to 42 days (each cycle is 14 days) | Will be summarized using mean +/- standard error of mean, range, and median at each time point. Graphical analyses will be largely used to assess potential patterns and relationships. |
| Change in FCGRT/FcRn expression | Day 1 of cycle 1, 3, 5, 7 (each cycle is 14 days) | Will be assessed using peripheral blood and summarized using mean +/- standard error of mean, range, and median at each time point. Graphical analyses will be largely used to assess potential patterns and relationships. |
Countries
United States
Outcome results
None listed